<DOC>
	<DOCNO>NCT01584687</DOCNO>
	<brief_summary>Objectives : 1 . Determine mRNA expression could use biomarker predict monitor response omalizumab patient difficult control asthma 2 . Identify gene switch switch use Omalizumab . Methods : This study open label clinical trial , six patient . The patient receive Omalizumab accord age weight ( maximum dose : 375 mg every 15 day ) 4 month . There run-in period one month , allergic asthma diagnosis confirm treatment optimize . Patients evaluate blood sample collect 3 occasion : beginning , 2 month baseline end study . Blood sample always collect one week last omalizumab dose . Primary outcome RNA expression 20 gene measure real time-PCR ( high-affinity IgE receptor , IL-4 , IL-5 , IL-13 , gama-IFN , quimokines , Fc epsilon , others ) . Secondary outcome ACT , ACQ spirometry .</brief_summary>
	<brief_title>mRNA Expression Biomarker Omalizumab Response</brief_title>
	<detailed_description>Study rational : There biomarker predict patient respond Omalizumab respond . Nowadays , monitor therapeutic response Omalizumab base clinical spirometric data . On hand , medication administer , main expected effect , also act target various direct indirect effect . We know gene switch switch use Omalizumab . For example , anti-IgE develop block serum total IgE thereby improve control allergic asthma . However , study note Omalizumab also reduce receptor FcepsilonRI , may implications treatment autoimmune urticaria .</detailed_description>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>12 year severe asthma control despite medication IgE 70 1300 IU/ml evidence allergy clinical history and/or skin test blood . previous use omalizumab smoke history</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>asthma</keyword>
	<keyword>difficult-to-control asthma</keyword>
	<keyword>mRNA expression</keyword>
	<keyword>biomarker</keyword>
	<keyword>real time PCR</keyword>
	<keyword>ACT</keyword>
	<keyword>ACQ</keyword>
</DOC>